Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.

Exclusion of patients with elevated plasma ptau181, potentially through excluding patients with extensive cortical neurodegeneration, enriches for a DLB patient population that is more responsive to neflamapimod. More generally, plasma biomarkers of AD co-pathology at study entry should be considered as stratification variables in DLB clinical trials. NCT04001517 at clinicaltrials.gov.